Revolution Medicines

RVMD

Market cap $14.8B

Revolution Medicines, Inc. ( RVMD ) Jefferies London Healthcare Conference 2025 November 18, 2025 4:30 AM EST Company Participants Mark Goldsmith - CEO, President & Chairman Conference Call Participants Yuxi Dong - Jefferies LLC, Research Division Presentation Yuxi Dong Jefferies LLC, Research Division Good morning, everyone. Let's get started.

Revolution Medicines, Inc. ( RVMD ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 9:00 AM EST Company Participants Mark Goldsmith - CEO, President & Chairman Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC, Research Division All right. So we'll get started right away.

RVMD posts a wider Q3 loss as rising R&D and administrative costs weigh, while its RAS(ON) pipeline advances toward key 2026 data.

Revolution Medicines, Inc. ( RVMD ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Ryan Asay - Senior Vice President of Corporate Affairs Mark Goldsmith - CEO, President & Chairman Wei Lin - Chief Medical Officer Jack Anders - Chief Financial Officer Alan Bart Sandler - Chief Development Officer Anthony Mancini Stephen Kelsey - President of Research & Development Conference Call Participants Jonathan Chang - Leerink Partners LLC, Research Division Yue-Wen Zhu - LifeSci Capital, LLC, Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Morgan Lamberti - Goldman Sachs Group, Inc., Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Marc Frahm - TD Cowen, Research Division Leonid Timashev - RBC Capital Markets, Research Division Jenna Li - Jefferies LLC, Research Division Asthika Goonewardene - Truist Securities, Inc., Research Division Alec Stranahan - BofA Securities, Research Division Joseph Catanzaro - Mizuho Securities USA LLC, Research Division Laura Prendergast - Stifel, Nicolaus & Company, Incorporated, Research Division Ami Fadia - Needham & Company, LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Revolution Medicines Q3 2025 Earnings Conference Call.

Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026 Company has initiated RASolute 304, a Phase 3 clinical trial of daraxonrasib as adjuvant treatment for patients with resectable PDAC, and remains on track to initiate RASolute 303 for patients with first line metastatic PDAC this year Daraxonrasib has received FDA Breakthrough Therapy Designation, Orphan Drug Designation and a Commissioner's National Priority Voucher New leadership appointments strengthened global development and commercialization capabilities Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif.

REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A.

REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter of 2025 on Wednesday, November 5, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to daraxonrasib, the company's RAS(ON) multi-selective inhibitor, for the treatment of pancreatic cancer.

REDWOOD CITY, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clinical data for elironrasib, a RAS(ON) G12C-selective inhibitor, in previously treated patients with KRAS G12C non-small cell lung cancer (NSCLC) who had received a prior KRAS(OFF) G12C inhibitor. These results will be highlighted in an oral presentation at the AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics in Boston, October 23-25.

Biotech stocks Disc Medicine and Revolution Medicines jumped Friday after the duo received some of the first CNPVs.